Total Payments
$731,971
2024 Payments
$83,994
Companies
45
Transactions
744
Medicare Patients
1,799
Medicare Billing
$538,903
Payment Breakdown by Category
Other$500,533 (68.4%)
Consulting$146,500 (20.0%)
Travel$67,891 (9.3%)
Food & Beverage$16,911 (2.3%)
Education$135.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $499,783 | 167 | 68.3% |
| Consulting Fee | $146,500 | 49 | 20.0% |
| Travel and Lodging | $67,891 | 110 | 9.3% |
| Food and Beverage | $16,911 | 413 | 2.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $750.00 | 1 | 0.1% |
| Education | $135.99 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $228,907 | 156 | $0 (2024) |
| Celgene Corporation | $168,919 | 214 | $0 (2024) |
| BeiGene USA, Inc. | $75,743 | 45 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $63,236 | 34 | $0 (2024) |
| Janssen Biotech, Inc. | $46,499 | 43 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $38,362 | 23 | $0 (2017) |
| Amgen Inc. | $35,749 | 45 | $0 (2024) |
| GlaxoSmithKline, LLC. | $28,453 | 16 | $0 (2024) |
| Genentech USA, Inc. | $15,722 | 16 | $0 (2023) |
| GENZYME CORPORATION | $13,781 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $83,994 | 135 | Janssen Biotech, Inc. ($27,275) |
| 2023 | $150,366 | 183 | BeiGene USA, Inc. ($33,361) |
| 2022 | $105,747 | 120 | Takeda Pharmaceuticals U.S.A., Inc. ($49,923) |
| 2021 | $86,621 | 59 | Takeda Pharmaceuticals U.S.A., Inc. ($26,259) |
| 2020 | $43,239 | 25 | Takeda Pharmaceuticals U.S.A., Inc. ($21,552) |
| 2019 | $114,814 | 102 | Celgene Corporation ($73,816) |
| 2018 | $81,912 | 68 | Takeda Pharmaceuticals U.S.A., Inc. ($47,843) |
| 2017 | $65,276 | 52 | Millennium Pharmaceuticals, Inc. ($38,362) |
All Payment Transactions
744 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: Genetically Defined Disease | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $32.14 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $166.43 | General |
| Category: Oncology | ||||||
| 12/08/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug), SCEMBLIX | Food and Beverage | In-kind items and services | $11.88 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $1,081.51 | General |
| Category: Oncology | ||||||
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $79.00 | General |
| 12/06/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $61.09 | General |
| 12/06/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $27.77 | General |
| 12/05/2024 | Celgene Corporation | ABECMA (Biological) | Food and Beverage | Cash or cash equivalent | $74.03 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $24.94 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Janssen Global Services, LLC | TECVAYLI (Biological) | Consulting Fee | Cash or cash equivalent | $637.65 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $3.29 | General |
| 11/22/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $1.50 | General |
| 11/21/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $8.86 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $26.45 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $25.62 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $1.37 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: Immunology | ||||||
| 11/05/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $7.29 | General |
| Category: Oncology | ||||||
| 11/04/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $33.75 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 411 | 1,379 | $403,503 | $132,128 |
| 2022 | 7 | 447 | 1,485 | $398,953 | $158,766 |
| 2021 | 9 | 473 | 1,303 | $354,578 | $141,728 |
| 2020 | 9 | 468 | 1,223 | $330,114 | $106,281 |
Total Patients
1,799
Total Services
5,390
Medicare Billing
$538,903
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 119 | 707 | $224,119 | $75,187 | 33.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 40 | 258 | $81,786 | $27,106 | 33.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 91 | 169 | $26,702 | $7,422 | 27.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 27 | 79 | $18,328 | $7,061 | 38.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 51 | 55 | $24,805 | $6,884 | 27.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 40 | 58 | $13,630 | $4,053 | 29.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $5,902 | $1,744 | 29.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 17 | 27 | $4,266 | $1,369 | 32.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 13 | $3,965 | $1,303 | 32.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 117 | 665 | $210,805 | $72,040 | 34.2% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 61 | 232 | $37,120 | $36,935 | 99.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 35 | 190 | $60,230 | $21,167 | 35.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 89 | 157 | $24,806 | $7,502 | 30.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 27 | 88 | $20,416 | $7,090 | 34.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 35 | 42 | $18,942 | $6,400 | 33.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 58 | 72 | $16,920 | $4,939 | 29.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 13 | 27 | $4,266 | $1,374 | 32.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 12 | 12 | $5,448 | $1,318 | 24.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 108 | 576 | $182,592 | $63,540 | 34.8% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 50 | 199 | $31,840 | $32,334 | 101.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 28 | 130 | $41,210 | $14,660 | 35.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 59 | 61 | $27,511 | $8,865 | 32.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 86 | 145 | $22,910 | $7,008 | 30.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 58 | 82 | $19,270 | $5,789 | 30.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 34 | 57 | $13,224 | $4,469 | 33.8% |
About Saulius Girnius
Saulius Girnius is a Hematology & Oncology healthcare provider based in Montgomery, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/28/2008. The National Provider Identifier (NPI) number assigned to this provider is 1053586420.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Saulius Girnius has received a total of $731,971 in payments from pharmaceutical and medical device companies, with $83,994 received in 2024. These payments were reported across 744 transactions from 45 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($499,783).
As a Medicare-enrolled provider, Girnius has provided services to 1,799 Medicare beneficiaries, totaling 5,390 services with total Medicare billing of $538,903. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine, Hematology
- Location Montgomery, OH
- Active Since 04/28/2008
- Last Updated 01/23/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1053586420
Products in Payments
- NINLARO (Drug) $205,945
- Revlimid (Drug) $136,220
- BRUKINSA (Drug) $74,768
- Kyprolis (Drug) $35,657
- DARZALEX (Biological) $35,079
- Pomalyst (Drug) $31,448
- BLENREP (Biological) $28,416
- REBLOZYL (Biological) $25,174
- TECVAYLI (Biological) $14,009
- SARCLISA (Biological) $13,781
- Lunsumio (Biological) $11,346
- VENCLEXTA (Biological) $4,112
- JAYPIRCA (Drug) $3,125
- clonoSEQ (Device) $2,949
- Tibsovo (Drug) $2,353
- ABECMA (Biological) $2,104
- OPDIVO (Biological) $1,480
- IMBRUVICA (Drug) $416.32
- Tavalisse (Drug) $244.98
- EPKINLY (Drug) $195.24
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Montgomery
John Reardon, Md, MD
Hematology & Oncology — Payments: $6,253
Hematology & Oncology $6,253
Jackson Reynolds, Md, MD
Hematology & Oncology — Payments: $6,188
Hematology & Oncology $6,188
Rehan Ajmal Sarmad, Md, MD
Hematology & Oncology — Payments: $3,017
Hematology & Oncology $3,017
Astrid Belalcazar, Md, MD
Hematology & Oncology — Payments: $2,327
Hematology & Oncology $2,327
Keith Thompson, Md, MD
Hematology & Oncology — Payments: $1,700
Hematology & Oncology $1,700
Natalia Paez Arango
Hematology & Oncology — Payments: $873.76
Hematology & Oncology $873.76